Belonging to a class of class of prescription medications called dipeptidyl peptidase-4 (DPP-4) inhibitors, Merck's JANUVIA™(sitagliptin phosphate) has recently been approved by the USFDA for the treatment of type 2 diabetes.

In a recommended dose of 100 mg once daily, JANUVIA™ is designed to improve blood sugar (glucose) control in patients with type 2 diabetes when diet and exercise is not enough.

However, JANUVIA™ should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, because it will not give the same effect.

Read more from Merck's press release.

Photo Credit: [NY Times]